{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T16:20:49Z","timestamp":1794932449793,"version":"4.9.1"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.vaccine.2026.129080","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T21:21:31Z","timestamp":1787779291000},"page":"129080","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Residual DNA in COVID-19 mRNA vaccines: Regulatory context and misinformation"],"prefix":"10.1016","volume":"91","author":[{"given":"Takeshi","family":"Nitta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taku","family":"Kashiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihisa","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Toyoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Miyazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukari","family":"Kamijima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Kakeya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2026.129080_bb0005","unstructured":"Ministry of Health, Labour and Welfare Standards for biological products (revised) In Japanese. Enforced November 20; 2025."},{"key":"10.1016\/j.vaccine.2026.129080_bb0010","author":"Japanese Society of Nucleic Acids Therapeutics, Regulatory Science Division"},{"key":"10.1016\/j.vaccine.2026.129080_bb0015","series-title":"Analytical procedures for quality of mRNA vaccines and therapeutics: Draft Guidelines, 3rd Edition","author":"United States Pharmacopeia","year":"2024"},{"key":"10.1016\/j.vaccine.2026.129080_bb0020","series-title":"Draft guideline on the quality aspects of mRNA vaccines","author":"European Medicines Agency","year":"2025"},{"key":"10.1016\/j.vaccine.2026.129080_bb0025","series-title":"European pharmacopoeia. General text 5.36: mRNA vaccines for human use","author":"European Directorate for the Quality of Medicines & HealthCare","year":"2025"},{"key":"10.1016\/j.vaccine.2026.129080_bb0030","series-title":"European pharmacopoeia. General text 5.39: mRNA substances for the production of mRNA vaccines for human use","author":"European Directorate for the Quality of Medicines & HealthCare","year":"2025"},{"key":"10.1016\/j.vaccine.2026.129080_bb0035","series-title":"European pharmacopoeia. General text 5.40: DNA templates for the preparation of mRNA substances","author":"European Directorate for the Quality of Medicines & HealthCare","year":"2025"},{"key":"10.1016\/j.vaccine.2026.129080_bb0040","author":"McKernan"},{"key":"10.1016\/j.vaccine.2026.129080_bb0045","series-title":"WHO Technical Report Series No. 978, Annex 3: recommendations for the evaluation of animal cell cultures as substrates for the manufacture of biological medicinal products and for the characterization of cell banks","author":"World Health Organization","year":"2013"},{"key":"10.1016\/j.vaccine.2026.129080_bb0050","series-title":"Guidance for industry: characterization and qualification of cell substrates and other biological materials used in the production of viral vaccines for infectious disease indications","author":"U.S. Food and Drug Administration","year":"2010"},{"key":"10.1016\/j.vaccine.2026.129080_bb0055","series-title":"Q6B: specifications: test procedures and acceptance criteria for biotechnological\/biological products","author":"International Council for Harmonisation (ICH)","year":"1999"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129080_bb0060","doi-asserted-by":"crossref","DOI":"10.1080\/08916934.2025.2551517","article-title":"Quantification of residual plasmid DNA and SV40 promoter-enhancer sequences in Pfizer\/BioNTech and Moderna modRNA COVID-19 vaccines from Ontario, Canada","volume":"58","author":"Speicher","year":"2025","journal-title":"Autoimmunity"},{"issue":"3","key":"10.1016\/j.vaccine.2026.129080_bb0065","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3390\/mps7030041","article-title":"Methodological considerations regarding the quantification of DNA impurities in the COVID-19 mRNA vaccine Comirnaty","volume":"7","author":"K\u00f6nig","year":"2024","journal-title":"Methods Protoc"},{"key":"10.1016\/j.vaccine.2026.129080_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2025.127022","article-title":"Quantification of objective concentrations of DNA impurities in mRNA vaccines","volume":"55","author":"Kaiser","year":"2025","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.129080_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2025.127186","article-title":"Opting for the appropriate methodology for quantification of residual DNA impurities in mRNA vaccines","volume":"56","author":"Vieths","year":"2025","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129080_bb0080","doi-asserted-by":"crossref","DOI":"10.1038\/s41541-025-01304-9","article-title":"Systematic analysis of COVID-19 mRNA vaccines using four orthogonal approaches demonstrates no excessive DNA impurities","volume":"10","author":"Achs","year":"2025","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.vaccine.2026.129080_bb0085","author":"Catanzaro"},{"key":"10.1016\/j.vaccine.2026.129080_bb0090","author":"Nitta"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129080_bb0095","doi-asserted-by":"crossref","first-page":"6835","DOI":"10.1038\/s41598-023-33862-0","article-title":"High spontaneous integration rates of end-modified linear DNAs upon mammalian cell transfection","volume":"13","author":"Lim","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.vaccine.2026.129080_bb0100","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/s42003-019-0300-2","article-title":"Exosome-mediated horizontal gene transfer occurs in double-strand break repair during genome editing","volume":"2","author":"Ono","year":"2019","journal-title":"Commun. Biol."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26008893?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26008893?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T15:52:11Z","timestamp":1794930731000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X26008893"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":20,"alternative-id":["S0264410X26008893"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.129080","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Residual DNA in COVID-19 mRNA vaccines: Regulatory context and misinformation","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.129080","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"129080"}}